- Home
- JSPR vs VYGR Comparison
JSPR vs VYGR Comparison
Compare JSPR & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- VYGR
- Stock Information
- Founded
- JSPR 2018
- VYGR 2013
- Country
- JSPR United States
- VYGR United States
- Employees
- JSPR N/A
- VYGR N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- JSPR Health Care
- VYGR Health Care
- Exchange
- JSPR Nasdaq
- VYGR Nasdaq
- Market Cap
- JSPR 323.0M
- VYGR 309.7M
- IPO Year
- JSPR N/A
- VYGR 2015
- Fundamental
- Price
- JSPR $22.47
- VYGR $6.34
- Analyst Decision
- JSPR Strong Buy
- VYGR Strong Buy
- Analyst Count
- JSPR 11
- VYGR 9
- Target Price
- JSPR $73.38
- VYGR $16.44
- AVG Volume (30 Days)
- JSPR 190.3K
- VYGR 544.8K
- Earning Date
- JSPR 11-07-2024
- VYGR 11-12-2024
- Dividend Yield
- JSPR N/A
- VYGR N/A
- EPS Growth
- JSPR N/A
- VYGR N/A
- EPS
- JSPR N/A
- VYGR 0.47
- Revenue
- JSPR N/A
- VYGR $163,784,000.00
- Revenue This Year
- JSPR N/A
- VYGR N/A
- Revenue Next Year
- JSPR N/A
- VYGR N/A
- P/E Ratio
- JSPR N/A
- VYGR $13.27
- Revenue Growth
- JSPR N/A
- VYGR 3.40
- 52 Week Low
- JSPR $4.00
- VYGR $5.19
- 52 Week High
- JSPR $31.01
- VYGR $11.72
- Technical
- Relative Strength Index (RSI)
- JSPR 52.17
- VYGR 50.24
- Support Level
- JSPR $21.44
- VYGR $6.13
- Resistance Level
- JSPR $23.89
- VYGR $6.69
- Average True Range (ATR)
- JSPR 1.56
- VYGR 0.35
- MACD
- JSPR -0.13
- VYGR 0.06
- Stochastic Oscillator
- JSPR 34.01
- VYGR 51.11
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.